- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04570475
High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache
High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache: a Randomized, Double-blind, Placebo Controlled Trial.
This study intends to investigate the use of high-dose Vitamin D3 plus a multivitamin in the prevention of cluster headache attacks.
Participants can be enrolled anywhere in the United States that has access to one of our participating labs (for blood work - anticipated to be available in most of the USA).
The study may include:
- Screening: Participants may be interviewed, examined, fill out surveys, and get blood testing
- Week 1: baseline period (no added medications - to establish a baseline)
- Weeks 2-4: double-blinded experimental period - participants receive either 1) high-dose Vitamin D3 + multivitamin, or 2) placebo + multivitamin. Participants also fill out a survey and have blood testing.
- Weeks 5-7: open-label period - ALL participants receive high-dose Vitamin D3 + multivitamin. Participants also fill out a survey and may have blood testing.
Specifically, our primary outcome is the change from baseline to experimental weeks 1-3 in the frequency of cluster headache attacks between placebo and high-dose vitamin D. Specific primary and secondary outcomes are listed below.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Mark J Burish, MD,PhD
- Phone Number: (713) 486-7771
- Email: nctt.wec@uth.tmc.edu
Study Contact Backup
- Name: Celia Tran, BS
- Phone Number: (713) 486-7771
- Email: nctt.wec@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Mark J Burish, MD,PhD
- Phone Number: 713-486-7771
- Email: nctt.wec@uth.tmc.edu
-
Contact:
- Celia Tran, BS
- Phone Number: (713) 486-7771
- Email: nctt.wec@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A diagnosis of episodic cluster headache according to the International Classification of Headache Disorders 3rd edition as well as cluster periods that are predictable and have a duration of 6 weeks or greater and approximately one attack daily minimum OR
- A diagnosis of chronic cluster headache according to the International Classification of Headache Disorders 3rd edition as well as approximately one attack daily
- Participants who are unlikely to need to change their preventive cluster headache treatment regimen in the next 6 weeks.
Exclusion Criteria:
- Co-existing disease or other characteristic that precludes appropriate diagnosis of cluster headache.
- Active drug or alcohol use or dependence that, in the opinion of the site investigator,would interfere with adherence to study requirements.
- Inability or unwillingness of subject to give informed consent.
- Known allergy to study drug, multivitamin, or placebo components
- Pregnancy or lactation (breastfeeding)
- Usage of greater than 4,000 International Units of Vitamin D3 daily within 60 days of the beginning of the study.
- Concurrent use of Vitamin D and/or multivitamin along with the inability to stop them before the study begins.
- Liver failure or known coagulation disorder (as this study includes vitamin K) such as haemophilia, von Willebrand disease, Factor V Leiden, Antithrombin III deficiency, Protein C or S deficiency, or anti-phospholipid antibody syndrome.
- A personal medical history of more than 1 deep venous thrombosis and/or pulmonary embolism (as this study includes vitamin K).
- Current use of anticoagulants (as this study includes vitamin K). Anticoagulants include: apixaban (Eliquis), betrixaban (Bevyxxa), dabigatran (Pradaxa), dalteparin (Fragmin), edoxaban (Savaysa), enoxaparin (Lovenox), fondaparinux (Arixtra), heparin, rivaroxiban (Xarelto), and warfarin (Coumadin).
- Current use of medications that alter vitamin D metabolism, including steroids,interferon, phenytoin, phenobarbital, digitalis/digoxin, and thiazide diuretics (such as hydrochlorothiazide or chlorthalidone)
Participants who are aware that their most recent labwork in the last 2 years showed any of the following:
- 25-hydroxyvitamin D levels >75 nmol/L
- Elevated calcium level
- Elevated phosphate level
- Abnormal parathyroid hormone levels
- Elevated creatinine level
- Of note if any values are outside the acceptable range for the study, candidates may still participate in the study if the most recent lab testing is inside the acceptable range for the study. For example, if a candididate were taking a vitamin or medication that may have caused these elevated levels, but no longer take the vitamin or medication, they may be enrolled if retesting is normal.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: vitamin D+multivitamin
|
Participants will receive vitamin D+multivitamin for 3 weeks.
At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks.
At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
|
Active Comparator: placebo+multivitamin
|
Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks.
At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
Participants will receive placebo+multivitamin for 3 weeks.
At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in average weekly frequency of cluster headache attacks
Time Frame: (baseline, average of weeks 1-3)
|
First primary outcome
|
(baseline, average of weeks 1-3)
|
Change in average weekly frequency of cluster headache attacks
Time Frame: (baseline, week 3)
|
Second primary outcome
|
(baseline, week 3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who had a reduction of at least 50% in the weekly frequency of cluster headache attacks between baseline and week 3
Time Frame: (baseline, week 3)
|
(baseline, week 3)
|
|
Number of participants who had a reduction of at least 30% in the weekly frequency of cluster headache attacks between baseline and week 3
Time Frame: baseline, week 3
|
baseline, week 3
|
|
Change in number of abortive medications or other treatments used per week
Time Frame: baseline, week 3
|
baseline, week 3
|
|
Change in intensity of cluster headache attacks as assessed by numerical rating scale
Time Frame: baseline, week 3
|
Total score ranges from 0-10, and a higher score indicates a greater intensity of attacks
|
baseline, week 3
|
Change in number of participants whose disease is 'much better' or 'very much better' as assessed by the Patient Global Impression of Improvement Scale
Time Frame: baseline, week 3
|
With the Patient Global Impression of Improvement Scale, a patient is asked to rate their disease as Very much better, Much better, A little better, No change, A little worse, Much worse, or Very much worse compared to a reference point in the past
|
baseline, week 3
|
Change in quality of life as measured by the Cluster Headache Quality of life questionnaire
Time Frame: baseline, week 3
|
Total score ranges from 0-100, and a higher score indicates a better quality of life
|
baseline, week 3
|
Change in duration of cluster headache attacks, in minutes
Time Frame: baseline, week 3
|
baseline, week 3
|
|
Change in level of 25-hydroxyvitamin D
Time Frame: baseline, week 3
|
baseline, week 3
|
|
Change in average weekly frequency of cluster headache attacks
Time Frame: (baseline, week 6)
|
(baseline, week 6)
|
|
Number of participants who had a reduction of at least 50% in the weekly frequency of cluster headache attacks between baseline and week 6
Time Frame: (baseline, week 6)
|
(baseline, week 6)
|
|
Number of participants who had a reduction of at least 30% in the weekly frequency of cluster headache attacks between baseline and week 6
Time Frame: baseline, week 6
|
baseline, week 6
|
|
Change in number of abortive medications or other treatments used per week
Time Frame: baseline, week 6
|
baseline, week 6
|
|
Change in intensity of cluster headache attacks as assessed by numerical rating scale
Time Frame: baseline, week 6
|
Total score ranges from 0-10, and a higher score indicates a greater intensity of attacks
|
baseline, week 6
|
Change in number of participants whose disease is 'much better' or 'very much better' as assessed by the Patient Global Impression of Improvement Scale
Time Frame: baseline, week 6
|
With the Patient Global Impression of Improvement Scale, a patient is asked to rate their disease as Very much better, Much better, A little better, No change, A little worse, Much worse, or Very much worse compared to a reference point in the past
|
baseline, week 6
|
Change in quality of life as measured by the Cluster Headache Quality of life questionnaire
Time Frame: baseline, week 6
|
Total score ranges from 0-100, and a higher score indicates a better quality of life
|
baseline, week 6
|
Change in duration of cluster headache attacks, in minutes
Time Frame: baseline, week 6
|
baseline, week 6
|
|
Change in level of 25-hydroxyvitamin D
Time Frame: baseline, week 6
|
baseline, week 6
|
|
Number of days until end of the cluster period after the start of treatment (i.e., the time to the end of an episodic cluster cycle)
Time Frame: upto 3 weeks from treatment
|
upto 3 weeks from treatment
|
|
Change in average weekly frequency of cluster headache attacks
Time Frame: (baseline, week 2)
|
(baseline, week 2)
|
|
Change in average weekly frequency of cluster headache attacks
Time Frame: (baseline, week 1)
|
(baseline, week 1)
|
|
Change in intensity of cluster headache attacks as assessed by numerical rating scale
Time Frame: baseline, week 2
|
Total score ranges from 0-10, and a higher score indicates a greater intensity of attacks
|
baseline, week 2
|
Change in intensity of cluster headache attacks as assessed by numerical rating scale
Time Frame: baseline, week 1
|
Total score ranges from 0-10, and a higher score indicates a greater intensity of attacks
|
baseline, week 1
|
Change in duration of cluster headache attacks, in minutes
Time Frame: baseline, week 2
|
baseline, week 2
|
|
Change in duration of cluster headache attacks, in minutes
Time Frame: baseline, week 1
|
baseline, week 1
|
|
Change in number of abortive medications or other treatments used per week
Time Frame: baseline, week 2
|
baseline, week 2
|
|
Change in number of abortive medications or other treatments used per week
Time Frame: baseline, week 1
|
baseline, week 1
|
|
Change in quality of life as measured by the Cluster Headache Quality of life questionnaire
Time Frame: baseline, week 2
|
Total score ranges from 0-100, and a higher score indicates a better quality of life
|
baseline, week 2
|
Change in quality of life as measured by the Cluster Headache Quality of life questionnaire
Time Frame: baseline, week 1
|
Total score ranges from 0-100, and a higher score indicates a better quality of life
|
baseline, week 1
|
Change in level of 25-hydroxyvitamin D
Time Frame: baseline, week 2
|
baseline, week 2
|
|
Change in level of 25-hydroxyvitamin D
Time Frame: baseline, week 1
|
baseline, week 1
|
|
Change in level of calcium
Time Frame: baseline, week 3
|
baseline, week 3
|
|
Change in level of calcium
Time Frame: baseline, week 6
|
baseline, week 6
|
|
Change in level of calcium
Time Frame: baseline, week 2
|
baseline, week 2
|
|
Change in level of calcium
Time Frame: baseline, week 1
|
baseline, week 1
|
|
Change in level of phosphate
Time Frame: baseline, week 3
|
baseline, week 3
|
|
Change in level of phosphate
Time Frame: baseline, week 6
|
baseline, week 6
|
|
Change in level of phosphate
Time Frame: baseline, week 1
|
baseline, week 1
|
|
Change in level of phosphate
Time Frame: baseline, week 2
|
baseline, week 2
|
|
Change in level of parathyroid hormone
Time Frame: baseline, week 3
|
baseline, week 3
|
|
Change in level of parathyroid hormone
Time Frame: baseline, week 6
|
baseline, week 6
|
|
Change in level of parathyroid hormone
Time Frame: baseline, week 1
|
baseline, week 1
|
|
Change in level of parathyroid hormone
Time Frame: baseline, week 2
|
baseline, week 2
|
|
Change in level of creatinine
Time Frame: baseline, week 3
|
baseline, week 3
|
|
Change in level of creatinine
Time Frame: baseline, week 6
|
baseline, week 6
|
|
Change in level of creatinine
Time Frame: baseline, week 1
|
baseline, week 1
|
|
Change in level of creatinine
Time Frame: baseline, week 2
|
baseline, week 2
|
|
Change in number of participants whose disease is 'much better' or 'very much better' as assessed by the Patient Global Impression of Improvement Scale
Time Frame: baseline, week 2
|
With the Patient Global Impression of Improvement Scale, a patient is asked to rate their disease as Very much better, Much better, A little better, No change, A little worse, Much worse, or Very much worse compared to a reference point in the past
|
baseline, week 2
|
Change in number of participants whose disease is 'much better' or 'very much better' as assessed by the Patient Global Impression of Improvement Scale
Time Frame: baseline, week 1
|
With the Patient Global Impression of Improvement Scale, a patient is asked to rate their disease as Very much better, Much better, A little better, No change, A little worse, Much worse, or Very much worse compared to a reference point in the past
|
baseline, week 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mark J Burish, MD,PhD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Trigeminal Autonomic Cephalalgias
- Headache
- Cluster Headache
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Vitamin D
Other Study ID Numbers
- HSC-MS-20-0945
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cluster Headache
-
Diamond Headache ClinicGlaxoSmithKlineUnknownEpisodic Cluster Headache | Chronic Cluster HeadacheUnited States
-
Eli Lilly and CompanyCompletedEpisodic Cluster Headache | Chronic Cluster HeadacheSpain, United States, Finland, Germany, United Kingdom, Belgium, France, Denmark, Italy, Netherlands, Canada, Greece
-
Winston LaboratoriesNot yet recruitingEpisodic Cluster Headache
-
Man and Science, SARecruitingChronic Cluster HeadacheBelgium
-
Radboud University Medical CenterLeiden University Medical Center; ZonMw: The Netherlands Organisation for Health... and other collaboratorsNot yet recruitingChronic Cluster Headache
-
Leiden University Medical CenterUniversity of Copenhagen; Maastricht University Medical Center; Erasmus Medical... and other collaboratorsCompletedChronic Cluster HeadacheNetherlands, Belgium, Germany, Hungary
-
Hospices Civils de LyonNot yet recruitingCluster Headache, Episodic
-
H. Lundbeck A/SCompletedCluster Headache, EpisodicSpain, United States, Germany, Portugal, Italy, Netherlands, Finland, Belgium, Czechia, Denmark, France, Georgia, Russian Federation, United Kingdom, Greece, Estonia, Japan, Norway, Sweden
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedEpisodic Cluster HeadacheUnited States, Australia, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom, Canada
-
Eli Lilly and CompanyCompletedEpisodic Cluster HeadacheItaly, United States, Canada, Belgium, Denmark, Finland, France, Germany, Spain, United Kingdom, Netherlands, Greece
Clinical Trials on Vitamin D
-
PfizerTerminated
-
Umeå UniversityRegion SkaneCompleted
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SACompletedVitamin D Deficiency | Overweight and Obesity | Overweight AdolescentsColombia
-
Khon Kaen UniversityNot yet recruiting
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...CompletedVitamin D DeficiencySlovenia
-
USDA, Western Human Nutrition Research CenterCompletedVitamin D DeficiencyUnited States
-
University of AarhusNot yet recruitingImmune System Diseases | Growth | Child Development | Vitamin D Supplementation
-
University Hospital, Basel, SwitzerlandCompleted
-
Cornell UniversityArogyavaram Medical CentreNot yet recruiting
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting